{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Lymphocytic+Leukemia&page=36&q=SLL",
    "query": {
      "q": "SLL",
      "condition": "Chronic Lymphocytic Leukemia",
      "page": 36
    },
    "page_size": 10
  },
  "pagination": {
    "page": 36,
    "page_size": 10,
    "total_count": 909,
    "total_pages": 91,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Lymphocytic+Leukemia&page=37&q=SLL&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Lymphocytic+Leukemia&page=35&q=SLL&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-29T09:48:52.638Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01168921",
      "title": "Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "CLL",
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "Eltrombopag",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2010-11-03",
      "completion_date": "2022-03-07",
      "has_results": true,
      "last_update_posted_date": "2023-03-23",
      "last_synced_at": "2026-10-29T09:48:52.638Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01168921"
    },
    {
      "nct_id": "NCT00003406",
      "title": "Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Myeloproliferative Disorders",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Precancerous/Nonmalignant Condition",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "autologous bone marrow transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "bone marrow ablation with stem cell support",
          "type": "PROCEDURE"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Cancer Treatment Centers of America",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "Up to 65 Years"
      },
      "enrollment_count": 30,
      "start_date": "1997-10",
      "completion_date": "2000-03",
      "has_results": false,
      "last_update_posted_date": "2013-03-26",
      "last_synced_at": "2026-10-29T09:48:52.638Z",
      "location_count": 1,
      "location_summary": "Zion, Illinois",
      "locations": [
        {
          "city": "Zion",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003406"
    },
    {
      "nct_id": "NCT00003538",
      "title": "Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "graft versus host disease prophylaxis/therapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "allogeneic bone marrow transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "Up to 65 Years"
      },
      "enrollment_count": null,
      "start_date": "1997-03",
      "completion_date": "2004-05",
      "has_results": false,
      "last_update_posted_date": "2014-05-02",
      "last_synced_at": "2026-10-29T09:48:52.638Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003538"
    },
    {
      "nct_id": "NCT00176475",
      "title": "Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm"
      ],
      "interventions": [
        {
          "name": "rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "therapeutic allogeneic lymphocytes",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Medicine and Dentistry of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2005-01",
      "completion_date": "2008-02",
      "has_results": false,
      "last_update_posted_date": "2013-09-17",
      "last_synced_at": "2026-10-29T09:48:52.638Z",
      "location_count": 1,
      "location_summary": "New Brunswick, New Jersey",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00176475"
    },
    {
      "nct_id": "NCT00003567",
      "title": "Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors",
        "Lymphoma",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "therapeutic autologous lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "O6-benzylguanine",
          "type": "DRUG"
        },
        {
          "name": "carmustine",
          "type": "DRUG"
        },
        {
          "name": "temozolomide",
          "type": "DRUG"
        },
        {
          "name": "in vitro-treated peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 8,
      "start_date": "1999-05",
      "completion_date": "2007-02",
      "has_results": false,
      "last_update_posted_date": "2010-06-11",
      "last_synced_at": "2026-10-29T09:48:52.638Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003567"
    },
    {
      "nct_id": "NCT07024706",
      "title": "MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia (CLL)",
        "Small Lymphocytic Lymphoma (SLL)"
      ],
      "interventions": [
        {
          "name": "Acalabrutinib",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 80,
      "start_date": "2026-06-04",
      "completion_date": "2033-03-23",
      "has_results": false,
      "last_update_posted_date": "2026-10-23",
      "last_synced_at": "2026-10-29T09:48:52.638Z",
      "location_count": 4,
      "location_summary": "Boston, Massachusetts • Charlotte, North Carolina • Durham, North Carolina + 1 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07024706"
    },
    {
      "nct_id": "NCT00546793",
      "title": "Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "NHL",
        "Lymphoma, Non-Hodgkin",
        "Lymphoma, B-Cell",
        "Lymphoma, Follicular",
        "Lymphoma, Intermediate-Grade",
        "Lymphoma, Large-Cell",
        "Lymphoma, Low-Grade",
        "Lymphoma, Mixed-Cell",
        "Lymphoma, Small-Cell",
        "Leukemia, Lymphocytic, Chronic",
        "Leukemia, B-Cell, Chronic",
        "Leukemia, Prolymphocytic",
        "Leukemia, Small Lymphocytic",
        "Lymphoma, Small Lymphocytic",
        "Lymphoma, Lymphoplasmacytoid, CLL",
        "Lymphoplasmacytoid Lymphoma, CLL",
        "CLL",
        "SLL"
      ],
      "interventions": [
        {
          "name": "veltuzumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2008-01",
      "completion_date": "2013-03",
      "has_results": false,
      "last_update_posted_date": "2021-08-16",
      "last_synced_at": "2026-10-29T09:48:52.638Z",
      "location_count": 5,
      "location_summary": "Savannah, Georgia • Denville, New Jersey • Morristown, New Jersey + 2 more",
      "locations": [
        {
          "city": "Savannah",
          "state": "Georgia"
        },
        {
          "city": "Denville",
          "state": "New Jersey"
        },
        {
          "city": "Morristown",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00546793"
    },
    {
      "nct_id": "NCT02640833",
      "title": "A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "Small Lymphocytic Lymphoma",
        "Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Duvelisib",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 0,
      "start_date": "2016-07",
      "completion_date": "2021-02",
      "has_results": false,
      "last_update_posted_date": "2016-07-26",
      "last_synced_at": "2026-10-29T09:48:52.638Z",
      "location_count": 10,
      "location_summary": "Tucson, Arizona • Chicago, Illinois • Harvey, Illinois + 7 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Harvey",
          "state": "Illinois"
        },
        {
          "city": "Goshen",
          "state": "Indiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02640833"
    },
    {
      "nct_id": "NCT01752426",
      "title": "Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "Heavy Water (2H2O)",
          "type": "OTHER"
        },
        {
          "name": "PCI-32765",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2012-12-17",
      "completion_date": "2018-08-09",
      "has_results": true,
      "last_update_posted_date": "2020-02-24",
      "last_synced_at": "2026-10-29T09:48:52.638Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01752426"
    },
    {
      "nct_id": "NCT00068523",
      "title": "Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chronic Myeloproliferative Disorders",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Diseases"
      ],
      "interventions": [
        {
          "name": "anti-thymocyte globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "UV light therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "allogeneic bone marrow transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 10,
      "start_date": "2003-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2020-07-27",
      "last_synced_at": "2026-10-29T09:48:52.638Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00068523"
    }
  ]
}